Authors: Lomte DB, Bhosale RS, Jambdade V, Gore PR.
Aims and Objectives: To compare the efficacy, safety, and rate of response of intravenous iron sucrose and intramuscular iron Sorbitol therapy for anemia during pregnancy. Material and Methods: 100 antenatal cases of gestational age 16-32 weeks were included in this prospective study. Cases were randomly divided into two groups. Group A, having 50 cases received intravenous iron sucrose, and 50cases in group B received intramuscular iron sorbitol. Response to therapy in both groups was studied and compared. Results: The mean pretherapy hemoglobin in group A was 6.49 g/dl and in group B was 6.48 g/dl. The rise in hemoglobin after 4 weeks of starting therapy was 3.52 g/dl in group A and 2.33 g/dl in group B The difference was Statistically significant (P<0.01) The mean time taken to achieve target hemoglobin (>11 g/dl) was 6.37 weeks in group A and 9.04 weeks in group B. In group A, 8% (four) cases had grade I adverse effects. In group B, 24% (12) cases had grade I adverse effects. The difference was statistically significant (P=0.027). In both the groups no case discontinued the therapy. Conclusion: Intravenous iron sucrose is safe, convenient, more effective, and faster acting therapy than intramuscular iron sorbitol therapy for treating moderate to severe anemia during pregnancy.
Keywords: Iron sucrose, Iron sorbitol, Pregnancy, Iron deficiency.